Biotech Values

[ipollit77]

They already abandoned development on the drug once before

in line with other p38-inhibitor results they stopped development for all chronic inflammatory diseases...

Array BioPharma Stops Work on ARRY-797 Pan-Cytokine Inhibitor for RA Despite Good Early Data
July 16, 2009
by Janis Kelly

BOULDER, Colorado—Array BioPharma Inc announced that Phase 1b data from a 3-arm study of 28 rheumatoid arthritis (RA) patients ARRY-797 showed inhibition of C-reactive protein (CRP) levels during the first 3 weeks of dosing and a beneficial reduction in bone remodeling markers throughout treatment. There was also a trend toward lower pain scores over the 28-day course of the study. Nonetheless, the company is stopping development of ARRY-797 for RA and other chronic inflammatory diseases.

"In the 28-day RA study, ARRY-797 demonstrated a transient inhibition of the inflammatory biomarker CRP and a trend towards analgesic efficacy in the pain endpoint," said Kevin Koch, PhD, President and Chief Scientific Officer. "Since these results are similar to other p38 inhibitors evaluated in rheumatoid arthritis, these findings have led us to discontinue testing of ARRY-797 in chronic inflammatory diseases. We continue to believe that a p38 inhibitor holds promise in treating patients with cancer and sub-chronic pain."

Array has also stopped enrollment of new patients into a clinical trial of ARRY-797 in ankylosing spondylitis patients.